Trials / Terminated
TerminatedNCT02510560
Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants
A Multi-center, Double-blind, Randomized, Three-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- Elgan Pharma Ltd. · Industry
- Sex
- All
- Age
- 1 Day – 5 Days
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the effect of NTRA-2112 on intestinal malabsorption in preterm infants.
Detailed description
The study will assess the efficacy and safety of NTRA-2112 on intestinal malabsorption in preterm infants as compared to placebo
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NTRA-2112 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-10-09
- Primary completion
- 2018-04-25
- Completion
- 2018-04-25
- First posted
- 2015-07-29
- Last updated
- 2025-08-19
- Results posted
- 2025-06-06
Locations
50 sites across 10 countries: United States, Belgium, France, Germany, Hungary, Israel, Italy, Netherlands, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02510560. Inclusion in this directory is not an endorsement.